Literature DB >> 18708987

Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease.

Chung-Huang Tsai1, Tsai-Chung Li, Cheng-Chieh Lin.   

Abstract

BACKGROUND: Metabolic syndrome has been linked to nonalcoholic fatty liver disease (NAFLD).
OBJECTIVES: The purpose of the current study was to evaluate metabolic syndrome as a risk factor for NAFLD in Taiwanese adults.
METHODS: A cross-sectional study was conducted in which 876 subjects were enrolled. The diagnosis of NAFLD was made by abdominal ultrasonography. The Asia-Pacific modification of the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines was used to establish the diagnosis of metabolic syndrome.
RESULTS: NAFLD was diagnosed in 373 (42.6%) of the study population. Metabolic syndrome was diagnosed in 202 (23.1%) of the study population, and it was independently associated with NAFLD (odds ratio [OR] = 2.37; P < 0.001). Among the components of metabolic syndrome, hypertriglyceridemia (OR = 2.24; P < 0.001), hyperglycemia (OR = 2.23; P = 0.001), increased waist circumference (OR = 1.76; P = 0.013), and the diagnostic components of metabolic syndrome were independently associated with NAFLD.
CONCLUSION: Metabolic syndrome and some of its diagnostic components are independent risk factors for NAFLD.

Entities:  

Mesh:

Year:  2008        PMID: 18708987     DOI: 10.1097/SMJ.0b013e31817e8af9

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  17 in total

Review 1.  Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine.

Authors:  Mazen Noureddin; José M Mato; Shelly C Lu
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-13

Review 2.  Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index.

Authors:  Qing Pang; Jing-Yao Zhang; Si-Dong Song; Kai Qu; Xin-Sen Xu; Su-Shun Liu; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

Review 3.  Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations.

Authors:  Robert J Wong; Aijaz Ahmed
Journal:  World J Hepatol       Date:  2014-05-27

4.  Epidemiology of a fast emerging disease in the Asia-Pacific region: non-alcoholic fatty liver disease.

Authors:  Chan Wah-Kheong; Goh Khean-Lee
Journal:  Hepatol Int       Date:  2012-06-15       Impact factor: 6.047

Review 5.  NAFLD in Asia--as common and important as in the West.

Authors:  Geoffrey C Farrell; Vincent Wai-Sun Wong; Shiv Chitturi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-05       Impact factor: 46.802

6.  Nonalcoholic fatty liver disease and cardiovascular risk.

Authors:  Vijay Laxmi Misra; Mouen Khashab; Naga Chalasani
Journal:  Curr Gastroenterol Rep       Date:  2009-02

7.  A Comparison of the Liver Fat Score and CT Liver-to-Spleen Ratio as Predictors of Fatty Liver Disease by HIV Serostatus.

Authors:  Lauren E Mellor-Crummey; Jordan E Lake; Holly Wilhalme; Chi-Hong Tseng; Philip M Grant; Kristine M Erlandson; Jennifer C Price; Frank J Palella; Larry A Kingsley; Matthew Budoff; Wendy S Post; Todd T Brown
Journal:  J Clin Gastroenterol Hepatol       Date:  2018-07-30

8.  Wild bitter gourd improves metabolic syndrome: a preliminary dietary supplementation trial.

Authors:  Chung-Huang Tsai; Emily Chin-Fun Chen; Hsin-Sheng Tsay; Ching-jang Huang
Journal:  Nutr J       Date:  2012-01-13       Impact factor: 3.271

9.  Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population.

Authors:  Yongyuan Zhang; Tao Zhang; Chengqi Zhang; Fang Tang; Nvjuan Zhong; Hongkai Li; Xinhong Song; Haiyan Lin; Yanxun Liu; Fuzhong Xue
Journal:  BMJ Open       Date:  2015-09-22       Impact factor: 2.692

10.  Association between metabolic syndrome and the development of non-alcoholic fatty liver disease.

Authors:  Yi Wang; Yu Yuan Li; Yu Qiang Nie; Yong Jian Zhou; Chuang Yu Cao; Lin Xu
Journal:  Exp Ther Med       Date:  2013-04-29       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.